BioCentury
ARTICLE | Clinical News

Long-acting injectable iloperidone: Development discontinued

November 12, 2012 8:00 AM UTC

Titan disclosed in an SEC filing that Novartis decided to discontinue development of a long-acting, injectable formulation of iloperidone. Novartis will continue to commercialize Fanapt, an oral vers...